Clinical trials: Dementia, Frontotemporal
Dementia, Caregiver Burnout
WeCareAdvisor Study for Caregivers of People Living With Dementia
The WeCareAdvisor is an online tool to help caregivers manage behavioral and psychological symptoms of people living with dementia.
- Conditions
- Dementia, Caregiver Burnout, Caregiver Stress Syndrome, Alzheimer Disease
- Trial name
- NCT05012410
- Testing
- Immediate treatment group with High-Intensity Prompts, Immediate treatment group with Low-Intensity Prompts, Waitlist Control after three months with High-Intensity Prompts
- Where
- United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Drexel University
Mild Cognitive Impairment (MCI), Dementia
A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia
The goal of this clinical trial is to learn if an integrated protocol using multifocal non invasive brain stimulation and brain recording combined with cognitive training is effective in treating cognitive and affective…
- Conditions
- Mild Cognitive Impairment (MCI), Dementia, Alzheimer Disease, Early Onset, Alzheimer Disease
- Trial name
- MuSt-MID (NCT06668610)
- Testing
- StarStim 32, Neuroelectrics, Spain - Real multifocal tDCS, Cognitive treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Campania Luigi Vanvitelli
Mild Alzheimer's Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease
The purpose of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer's Disease.
- Trial name
- NCT03186989
- Testing
- IONIS MAPTRx
- Where
- 13 sites in Canada, Finland and 4 more
- Volunteers
- 46 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain…
- Trial name
- NCT06932809
- Testing
- 18F-JSS20-183A PET, Brain MRI, Amyloid PET
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Pennsylvania
Alzheimer Disease, Frontotemporal Dementia
Computational Tools for Early Diagnosis of Memory Disorders
The Virtual Physiological Human: DementiA Research Enabled by IT (VPH-DARE@IT) is a four-year IT-project funded through the European Union (EU).
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Dementia, Vascular, Mild Cognitive Impairment
- Trial name
- ProsKuopio (NCT02050464)
- Where
- 3 sites in Finland
- Volunteers
- 126 people
- Sponsor
- University of Eastern Finland
Sickle Cell Disease, Thalassemia
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
This is a clinical trial of bone marrow transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor.
- Conditions
- Sickle Cell Disease, Thalassemia, Anemia, Granuloma
- Trial name
- NCT00730314
- Testing
- Hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Children's Hospital Los Angeles
Alzheimer's Disease (AD), Lewy Body Dementia (LBD)
Social-cognitive Functioning: Validation of a New Neuropsychological Test
It is now established that disturbances in social cognition are frequent in neurology and that they contribute to the development of social conduct disorders.
- Conditions
- Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Frontotemporal Degeneration (FTD)
- Trial name
- REALSOCOG (NCT05558709)
- Testing
- REALSOCOG, BCS, Hetero-questionnaires
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer Disease, Amyotrophic Lateral Sclerosis
The Ontario Neurodegenerative Disease Research Initiative
The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a province-wide collaboration studying dementia and how to improve the diagnosis and treatment of neurodegenerative diseases including: Alzheimer's disease (AD)…
- Conditions
- Alzheimer Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson Disease
- Trial name
- ONDRI (NCT04104373)
- Testing
- Observational Cohort
- Where
- 12 sites in Canada
- Volunteers
- 522 people
- Sponsor
- Ontario Neurodegeneration Disease Research Initiative
Lysosomal Storage Disorders
Molecular and Cellular Mechanisms of Lysosomal Storage Diseases
The lysosome is a specialized part of the cell that functions to degrade metabolic wastes in the cell. Defects in the functioning of the lysosome result in accumulation and subsequent storage of such metabolic wastes.
- Trial name
- NCT02000310
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- O & O Alpan LLC
Alzheimer Disease, Dementia With Lewy Bodies
Cerebro Spinal Fluid Collection (CSF)
Cognitive neurodegenerative diseases are a major public health issue. At present, the diagnosis of certainty is still based on anatomopathological analyses.
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Parkinson's Disease Dementia
- Trial name
- Analzheimer (NCT04844060)
- Testing
- Lumbar punction
- Where
- France
- Volunteers
- 10,000 people
- Sponsor
- University Hospital, Strasbourg, France
Primary Progressive Aphasia, PPA
Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy
People with Primary Progressive Aphasia (PPA) are is a debilitating disorder characterized by the gradual loss of language functioning, even though cognitive functioning is relatively well preserved until the advanced stages of…
- Trial name
- NCT03728582
- Testing
- Active tDCS plus Speech-Language Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins University
Mild Dementia, Mild Cognitive Impairment
The Swedish BioFINDER - Primary Care Study
The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics.
- Conditions
- Mild Dementia, Mild Cognitive Impairment, SCD, Alzheimer Disease
- Trial name
- ADetect (NCT06120361)
- Testing
- Plasma APS 2 score, Plasma p-tau217/np-tau217, Plasma p-tau217
- Where
- Sweden
- Volunteers
- 1,200 people
- Sponsor
- Skane University Hospital
Alzheimer's Disease
Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid
This study will determine if biomarkers found in the cerebrospinal fluid of people with Alzheimer's disease, are affected by treatment with two common antibiotics, doxycycline and rifampicin, suggesting a disease-modifying effect…
- Trial name
- NCT00439166
- Testing
- doxycycline, rifampicin
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Hamilton Health Sciences Corporation
Alzheimer's Disease
Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination
Dementia is a common neurodegenerative syndrome in aged population. Alzheimer's disease (AD) is the most common disease. The main pathological findings in AD include senile plaques (SP) and neurofibrillary tangles (NFT).
- Trial name
- PMPBB3/AV45 (NCT04305210)
- Testing
- F-18 PMPBB3, 18F-florbetapir
- Where
- Taiwan
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Caregivers Burnout, Frontotemporal Dementia
Support Via Technology: Living and Learning With Advancing FTD
Much effort over the last several decades has been devoted to developing and implementing psychoeducational interventions for family caregiving partners for those with Alzheimer's and relatedm dementias (ADRD).
- Trial name
- STELLA-FTD (NCT05338710)
- Testing
- STELLA-FTD
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Dementia, Neurodegenerative Diseases
Retinal Hyperspectral Imaging in Neurodegenerative Diseases
Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths.
- Conditions
- Dementia, Neurodegenerative Diseases, Alzheimer Disease, Parkinson Disease
- Trial name
- NCT07545473
- Testing
- Hyperspectral camera
- Where
- Australia
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Mild Cognitive Impairment
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure.
- Trial name
- LATTICE (NCT03185208)
- Testing
- Lithium Carbonate
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Ariel Gildengers, MD
Niemann-Pick Disease Type C
Application of Miglustat in Patients With Niemann-Pick Type C
To evaluate the changes in cognitive function after miglustat treatment in Niemann-Pick type C patients.
- Trial name
- NCT01760564
- Testing
- Miglustat
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Amyotrophic Lateral Sclerosis, ALS
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).
- Trial name
- NCT05163886
- Testing
- LAM-002A
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- IRulya Therapeutics Inc.
Niemann-Pick Disease, Type C
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Niemann-Pick type C disease (NPC).
- Trial name
- NCT03759639
- Testing
- IB1001
- Where
- 9 sites in United States, Germany and 3 more
- Volunteers
- 33 people
- Sponsor
- IntraBio Inc